Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms ETNA
- 07 Jun 2017 Biomarkers information updated
- 21 Apr 2017 Planned End Date changed from 1 Oct 2025 to 31 Dec 2025.
- 07 Jul 2016 This trial was prematurely ended in Austria.